High dose cytarabine (HiDAC) with amsacrine (AMSA) for relapsed and refractory adult lymphoblastic leukemia (ALL): Ongoing single institution experience

被引：0
|
作者：
Monahan, BP
Dahut, WL
机构：
[1] NATL NAVAL MED CTR, DIV HEMATOL, BETHESDA, MD USA
[2] NATL NAVAL MED CTR, DIV MED ONCOL, BETHESDA, MD USA
来源：
BLOOD | 1995年 / 86卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3072 / 3072
页数：1
相关论文
共 50 条
  • [31] High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia
    Cortes, J
    Estey, E
    O'Brien, S
    Giles, F
    Shen, Y
    Koller, C
    Beran, M
    Thomas, D
    Keating, M
    Kantarjian, H
    CANCER, 2001, 92 (01) : 7 - 14
  • [32] GIMEMA ALL - Rescue 97: a salvage strategy for primary refractory or relapsed adult acute lymphoblastic leukemia
    Camera, A
    Annino, L
    Chiurazzi, F
    Fazi, P
    Cascavilla, N
    Fabbiano, F
    Marmont, F
    Di Raimondo, F
    Recchia, A
    Vignetti, M
    Rotoli, B
    Mandelli, F
    HAEMATOLOGICA, 2004, 89 (02) : 145 - 153
  • [33] Clofarabine-based chemotherapy for relapsed/refractory adult acute lymphoblastic leukemia and lymphoblastic lymphoma. The Spanish experience
    Barba, Pere
    Sampol, Antonia
    Calbacho, Maria
    Gonzalez, Jose
    Serrano, Josefina
    Martinez-Sanchez, Pilar
    Fernandez, Pascual
    Garcia-Boyero, Raimundo
    Bueno, Javier
    Maria Ribera, Josep
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (06) : 631 - 634
  • [34] Phase II study of liposomal vincristine (lipoV) in relapsed or refractory adult acute lymphoblastic leukemia (ALL).
    Thomas, DA
    Sarris, A
    O'Brien, S
    Cortes, J
    Giles, FJ
    Faderl, S
    Keating, MJ
    Burge, C
    Cabanillas, F
    Kantarjian, H
    BLOOD, 1999, 94 (10) : 238B - 238B
  • [35] A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia
    Karanes, C
    Kopecky, KJ
    Head, DR
    Grever, MR
    Hynes, HE
    Kraut, EH
    Vial, RH
    Lichtin, A
    Nand, S
    Samlowski, WE
    Appelbaum, FR
    LEUKEMIA RESEARCH, 1999, 23 (09) : 787 - 794
  • [36] TREATMENT OF REFRACTORY ADULT LYMPHOBLASTIC-LEUKEMIA (ALL) WITH 4'(9-ACRIDINYLAMINO) METHANESULFON-M-ANISIDIDE (AMSA)
    ARLIN, ZA
    FANUCCHI, MP
    GEE, TS
    KEMPIN, SJ
    MERTELSMANN, R
    YOUNG, CW
    CLARKSON, BD
    BLOOD, 1982, 60 (05) : 1224 - 1226
  • [37] A phase II study of high dose ARA-C and mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic leukemia
    Rosen, PJ
    Rankin, C
    Head, DR
    Boldt, DH
    Luthardt, FW
    Norwood, T
    Pugh, RP
    Karanes, C
    Appelbaum, FR
    LEUKEMIA RESEARCH, 2000, 24 (03) : 183 - 187
  • [38] A phase I trial of liposomal daunorubicin (Daunoxome®) administered with high-dose cytarabine (HiDAC) to patients (pts) with relapsed acute leukemia (AL).
    Cripe, L
    Kneebone, P
    Roberts, L
    Mukwaya, G
    Rutledge, C
    Gordon, M
    BLOOD, 1998, 92 (10) : 233A - 233A
  • [39] Nelarabine is safe and effective in adult relapsed or refractory T cellacute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL): The Bologna experience
    Papayannidis, Cristina
    Iacobucci, Ilaria
    Abbenante, Mariachiara
    Lonetti, Annalisa
    Guadagnuolo, Viviana
    Ferrrari, Anna
    Ottaviani, Emanuela
    Curti, Antonio
    Paolini, Stefania
    Parisi, Sarah
    Clissa, Cristina
    Baccarani, Michele
    Martinelli, Giovanni
    CANCER RESEARCH, 2011, 71
  • [40] Venetoclax in Combination with Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Single-Centre Experience
    Piccini, Matteo
    Pilerci, Sofia
    Scappini, Barbara
    Mannelli, Francesco
    Ciolli, Gaia
    Pasquini, Andrea
    Fasano, Laura
    Quinti, Elisa
    Guglielmelli, Paola
    Mannarelli, Carmela
    Pancani, Fabiana
    Zizza, Michela
    Signori, Leonardo
    Vannucchi, Alessandro M.
    Gianfaldoni, Giacomo
    BLOOD, 2022, 140 : 9008 - 9009
12345